FibroGen's GAAP loss for 3 months of 2022 was $63.205 million, down 11.9% from $71.755 million in the prior year. Revenue increased by 58.3% to $60.827 million compared to $38.429 million a year earlier.
FibroGen's GAAP loss for 3 months of 2022 was $63.205 million, down 11.9% from $71.755 million in the prior year. Revenue increased by 58.3% to $60.827 million compared to $38.429 million a year earlier. 
fibrogen.gcs-web.com
English (US) 